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Abstract: Sleep disorders occur commonly in Parkinson’s disease (PD), and reduce quality of 
life. Sleep-related problems in PD include insomnia, restless legs syndrome, rapid eye movement 
sleep behavior disorder, sleep apnea, parasomnias, excessive daytime sleepiness, and sleep 
attacks. This article reviews sleep disorders and their treatment in PD.
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Introduction
Sleep disorders occur commonly in Parkinson’s disease (PD), and were initially noted 
by James Parkinson in his original monograph. Recent estimates place the prevalence 
of sleep disturbance in PD at almost 100%.1,2 Sleep-related problems in PD can be 
divided into disturbances of sleep and wakefulness. Disturbances of sleep include 
insomnia, restless legs syndrome, rapid eye movement (REM) sleep behavior disorder, 
sleep apnea, and parasomnias. Disturbances of wakefulness include excessive daytime 
sleepiness (EDS) and sleep attacks. Sleep disorders are a major cause of disability 
in PD patients, and may have a substantial impact on quality of life. This review will 
focus on the etiology and treatment of sleep disorders in PD.
Somnolence and excessive daytime sleepiness
Somnolence and EDS occur commonly in PD. Etiologies of somnolence in PD include 
reversal of the sleep–wake cycle, the disease process itself, disrupted sleep due to a 
variety of motor and nonmotor causes, and the use of dopamine agonists and other 
antiparkinsonian medications. Several studies have found that dopamine agonists are 
more likely to cause somnolence than levodopa. The soporific effects of the commonly 
used dopamine agonists appear to be similar as assessed by Epworth Sleepiness Scale 
(ESS) scores.3–6
The use of pramipexole as monotherapy in mild to moderate PD was found to 
cause somnolence in 18% of pramipexole-treated patients compared to roughly 9% 
of placebo-treated patients.7 In a five-year study comparing ropinirole and levodopa 
as initial therapy, the incidence of somnolence was approximately 27% in ropinirole-
treated patients and 19% in levodopa-treated patients. Another randomized placebo-
controlled trial assessing the efficacy and safety of ropinirole in treating early PD 
found that somnolence occurred in 36% of ropinirole-treated patients compared 
to approximately 5% of patients taking placebo.8 Somnolence that is caused by 
dopamine agonists may be dose related, but may also emerge or worsen after a Neuropsychiatric Disease and Treatment 2009:5 536
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period of time on a stable dose. In a retrospective review 
of clinical trial data, Hauser and colleagues found that 
early PD patients experienced the onset of worst reported 
somnolence 10 ± 1.5 months (range 0.03–22 months) after 
starting pramipexole and after 6.7 ± 1.5 months at their 
maximum dose.9
EDS occurs in PD patients, and is usually associated with 
dopamine agonist use. EDS may occur with use of other 
PD medications, including levodopa/carbidopa. However, 
EDS as measured by the ESS does not always correspond 
to shortened sleep latency as quantified by the Multiple 
Sleep Latency Test (MSLT).10 In addition, nocturnal sleep 
disturbance as measured by polysomnogram (PSG) may 
not account for the “severity” of daytime sleepiness in PD 
patients with EDS.10
Treatment of EDS warrants a review of all medications, 
and elimination of possible offending agents when feasible. 
Nonantiparkinsonian medications that are associated with 
sleepiness such as benzodizapines should be reduced and 
discontinued. If EDS developed during or shortly after 
the introduction of an antiparkinsonian medication, that 
medication should be reduced if possible, and discontinued. 
Patients with EDS that does not resolve with medication 
changes should undergo an overnight sleep PSG to 
exclude the presence of a treatable sleep disorder such as 
sleep apnea.
Several studies have assessed the therapeutic effectiveness 
of modafinil, a medication that is US Food and Drug 
Administration (FDA)-approved to treat narcolepsy, in the 
treatment of EDS in patients with PD.11–13 Two studies found 
that modafinil improved EDS on a subjective level using the 
ESS,12,13 while a third study reported some subjective, but 
nonsignificant, improvements using the ESS.11 However, there 
was no objective improvement in EDS as measured by the 
MSLT in two studies that found objective improvement.11,13 
The possible ramifications of this are concerning if patients 
subjectively feel that their EDS is improved enough to 
drive, for example, but may, in fact, still suffer from EDS. 
Dextroamphetamine and methamphetamine may improve 
EDS, but have high abuse potential and should be used with 
caution. Pemoline, another stimulant, is associated with 
potential hepatotoxicity. Additional side effects of stimulants 
include headaches, irritability, nervousness, tremulous-
ness, insomnia, anorexia, gastrointestinal disturbances, and 
palpitations.14
The issue of driving safety should be discussed with all 
PD patients and caregivers, particularly those patients who 
suffer from EDS or somnolence. Patients should be informed 
that sleepiness is common in PD and may be associated 
with the disease itself, or caused by sleep disorders or 
medications. Because EDS and somnolence may occur 
during the initial titration of dopaminergic medications, 
particularly dopamine agonists, patients should be started 
on the lowest doses of these medications possible. Patients 
should be routinely asked about EDS during visits. Those 
patients who do suffer from substantial EDS and who 
doze off with little or no warning should not drive.
Sleep attacks (unintended 
sleep episodes)
A “sleep attack” describes “an event of overwhelming 
sleepiness that occurs without warning, or with a prodrome 
that is sufficiently short or overpowering to prevent the 
patient from taking appropriate protective measures”.15 The 
term “sleep attack” re-emerged in 1999 when Frucht and 
colleagues described sudden episodes of falling asleep that 
caused driving accidents.15 Several experts have suggested 
that the term “unintended sleep episodes (USE)” is a more 
appropriate description of these events, arguing that the word 
“attack” fails to recognize the background of sedation that 
may precede the onset of sleep.16,17 Patients experiencing 
“sleep attacks” may fall asleep because they are continuously 
sleepy, and then fall asleep in situations where resistance 
to sleep is decreased.18 However, patients may suffer from 
discreet waves of irresistible sleepiness that occur against 
a perceived background of normal wakefulness.19 When 
prodromes of sleepiness occur, they are often marked by 
yawning, blinking, or tearing.
One prospective survey of 236 PD patients found that 
72 (30.5%) reported sudden sleep episodes.20 Another 
study that used structured telephone interviews in 2,952 
PD patients in two German counties found that 177 (6%) 
patients had “sleep attacks”.21 Ninety-one patients had at least 
one sleep attack without a warning sign, while 86 patients 
always had a warning sign prior to a sleep attack. Seventy-
five percent of patients who experienced “sleep attacks” 
had an ESS score of greater than 10, while 37% of patients 
had an ESS score of greater than 15.
“Sleep attacks” may be caused by antiparkinsonian medi-
cations, usually dopamine agonists. One retrospective review 
of sleep attacks or narcoleptic-like events in PD found that 
these events occurred in 6.6% of patients taking dopamine 
agonists.22 The package insert for pramipexole in the United 
States recommends that patients must be informed that they 
should not drive a vehicle or engage in potentially dangerous 
activities until they have enough experience to gauge whether Neuropsychiatric Disease and Treatment 2009:5 537
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pramipexole adversely affects their mental performance.23 
“Sleep attacks” may also occur with other antiparkinsonian 
medications, including levodopa and entacapone.
Motor vehicle accidents and “sleep attacks” were first 
reported by Frucht and colleagues in a case series.15 Frucht 
and colleagues later determined that of approximately 400 PD 
patients who took pramipexole at three New York centers, 
there was an annual incidence of sleep attacks causing auto-
mobile accidents of 2%.24 Hauser and colleagues conducted a 
retrospective chart review of 37 PD patients who participated 
in pramipexole clinical trials.25 Using structured interviews 
with patients who reported moderate to severe somnolence, 
the yearly automobile accident rate due to falling asleep 
was calculated to be 1.6%. Hobson and colleagues found 
that of 638 PD patients, almost 4% of patients reported 
experiencing at least one episode of sudden sleep while 
driving after they were diagnosed with PD.26 Another study 
by Ondo and colleagues found that almost 23% of patients 
reported falling asleep at the wheel.27 Falling asleep while 
driving is associated with older age (odds ratio [OR] = 0.96, 
95% confidence interval [CI]: 0.93 to 0.99; P = 0.003), use 
of levodopa (OR = 2.96, 95% CI: 1.21 to 7.24; P = 0.018), 
and use of any dopamine agonist (OR = 3.08, 95% CI: 1.47 
to 6.42; P = 0.003). Brodsky and colleagues questioned 
101 consecutive PD patients and 100 non-PD age-matched 
controls about sleep habits and falling asleep while driving.28 
Almost 21% of PD drivers experienced sleep episodes, 
compared to 6% of controls (P  0.05). PD drivers who 
experienced a sleep episode while driving had greater ESS 
scores than patients who did not fall asleep at the wheel 
(ESS 11.62 ± 6.4 vs. 8.4 ± 4.1; P = 0.05).
Insomnia and Parkinson’s disease
Insomnia is a common complaint in patients with PD.29 
It appears to fluctuate over time in individual patients.30 
Insomnia in PD may occur as a direct consequence of the 
disease process itself31 or it may be secondary to factors 
associated with the condition, such as painful dystonia, 
nighttime reemergence of tremor, mood disturbances, and 
effects of medications, or nocturia.32–36 Insomnia in PD 
has also been associated with worse Montgomery–Asberg 
Depression Rating Scale scores and female sex.37 Disturbed 
sleep can have a significant impact on patients’ cognitive and 
physical function and may be associated with distress and 
depression. Insomnia also impacts patients’ and caregivers’ 
quality of life.38
Treatment of insomnia in PD patients first requires 
identifying its underlying causes. Interventions include 
adding levodopa/carbidopa or a dopamine agonist before 
bedtime if patients are awakened by painful dystonia, 
as well as treatment of urinary incontinence or discontinuing 
medications that contribute to insomnia.
Several controlled trials have evaluated the use of 
conventional sleeping aids as treatment for insomnia in PD. 
One study that evaluated the effect of levodopa/carbidopa 
on insomnia in PD found that when a sleep medication was 
administered at bedtime, sleep quality was improved from 
67% to 93% using a visual analog scale as well as early 
morning waking as measured by bed actigraphy.39 A second 
study looking at the use of levodopa/carbidopa slow release 
(SR) found that it did not improve the number of hours 
slept, number of awakenings, sleep latency, or general sleep 
satisfaction.40 However, there was a significant improvement 
in mean nocturnal akinesia score in the levodopa-treated 
group compared to the placebo group.
Melatonin, a hormone produced by the pineal gland, 
functions in regulating the circadian cycle by causing 
drowsiness.41 A study that measured nocturnal sleep by 
actigraphy, sleep diaries, and the ESS found that melatonin 
had a small benefit in treating insomnia in doses of 5 mg 
and 50 mg, with total sleep time improving by 10 minutes 
(from 5 hours 13 minutes to 5 hours 23 minutes; 3%) with 
the 50 mg dose of melatonin.42 However, another study found 
that melatonin 3 mg improved sleep quality by subjective, 
but not objective, measures (ie, PSG).43
Deep brain stimulation (DBS) is used to treat the 
symptoms of PD. Several studies using PSG found an 
improvement in sleep quality following DBS of the subtha-
lamic nucleus.44–46 However, DBS is not used primarily as a 
treatment for insomnia in PD.
Restless leg syndrome 
and Parkinson’s disease
Restless legs syndrome (RLS) is a neurological disorder 
characterized by an uncontrollable urge to move the legs, 
often related to unpleasant sensations in the legs while 
at rest. It occurs most often in the evening, and typically 
improves when moving the legs. Patient use various terms 
to describe the sensations of RLS, including “burning, 
creeping, crawling, or itching”. Estimates of the prevalence 
of RLS in PD patients have ranged from 3% to 20%.47 PD 
patients with RLS appear to have a longer duration of PD 
symptoms, more severe PD disability, a greater degree of 
cognitive dysfunction, and a longer duration of antipar-
kinson therapy than those without RLS.48 In one study, the 
most significant factor associated with the development Neuropsychiatric Disease and Treatment 2009:5 538
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of RLS in PD was the duration of antiparkinsonian 
therapy.48
Functional imaging studies suggest reduced dopami-
nergic function in the striatum in both RLS and PD.49,50 
The etiological relationship between PD and RLS remains 
unclear. While the dopamine agonists ropinirole and 
pramipexole are FDA-approved to treat moderate-to-severe 
primary RLS there are currently no controlled trials in PD 
patients with RLS. In non-PD patients, a single dose of 
pramipexole of between 0.125 and 0.750 mg that is ingested 
two to three hours before bedtime may adequately control 
sensory symptoms and motor signs of RLS.51 Clinical 
trials indicate that approximately 1.5 to 2 mg of ropinirole 
ingested before bedtime is effective in relieving symptoms 
of RLS, although doses in the trials ranged from 0.25–4.0 
mg once daily.52 Rotigotine (Neupro) is another nonergo-
line dopamine agonist with selectivity for D1, D2, and 
D3 receptors that is administered by 24-hour transdermal 
patches. Rotigotine was under review by the FDA as treat-
ment for RLS prior to it being withdrawn from the market 
due to crystallization.
REM sleep behavior disorder
REM sleep behavior disorder (RBD) is a type of 
parasomnia in which patients “act out” dramatic or violent 
dreams during the REM sleep stage. Nighttime behaviors 
for RBD patients include screaming, kicking, punching, 
or even injuring a bed partner. Recent evidence indicates 
that RBD may be a predictor of PD, as more than half 
of people who suffer from RBD may develop PD or 
parkinsonism within 12 years following their diagnosis, 
and almost an 18% will develop a neurodegenerative dis-
ease within five years of diagnosis.53 In another study of 
36 PD patients, the presence of RBD in PD was strongly 
associated with symptoms and signs of orthostatic hypo-
tension (systolic blood pressure lying to standing = -25.7 ± 
13.0 mmHg vs -4.9 ± 14.1 mmHg, P  0.001; and ortho-
static symptom prevalence = 71% vs 27%, P = 0.0076).54 
RBD in PD occurs more commonly in patients suffering 
from the nontremor-predominant subtype of the disease.55 
One study found that cognitive impairment in PD patients 
is closely related to the presence of REM sleep behavior 
disorder.56
Sleep apnea
Sleep apnea is a sleep disorder that is characterized by 
repetitive pauses in breathing during sleep that last long 
enough so that one or more breaths are missed. Central sleep 
apnea has been found to occur in neurodegenerative diseases 
including PD.
PD patients have an increased rate of snoring compared 
to controls, and some studies estimate that 20% of PD 
patients may suffer from sleep apnea despite normal body 
mass index.57 One case control study of 21 PD patients 
found that 20% had mild sleep apnea, while 23% had 
moderate to severe sleep apnea. Another study using poly-
somnographic evaluations also found a greater incidence 
of obstructive sleep apnea in PD patients compared to 
age-matched controls.58 However, another study evaluated 
100 PD patients (50 unselected, consecutive patients 
matched for age, sex and body mass index and 50 patients 
referred for sleepiness) and 50 in-hospital controls. Subjects 
underwent a video-polysomnography, and sleep apnea 
was found to be less frequent in the PD group (27% patients, 
including 6% with mild, 11% with moderate and 10% with 
severe sleep apnea) than in the in-hospital control group 
(40%, P  0.002). Sleep apnea in PD patients was not 
associated with increased sleepiness, nocturia, depression, 
cognitive impairment, or cardiovascular events. However, 
sleep apnea as more frequently identified and severe in the 
most disabled patients. Patients with PD did not display 
sleep hypoventilation, stridor or central sleep apnea. The 
authors concluded that obstructive sleep apnea does not 
seem to be a clinically relevant issue in PD, and that daytime 
sleepiness, nocturia and cognitive impairment are mostly 
caused by other, nonapneic mechanisms.59
Treatment for sleep apnea includes oxygen use, weight 
loss, continuous positive airway pressure (CPAP), or bilevel 
positive airway pressure (BiPAP). Polysomnography may 
be used to determine the presence and baseline severity of 
sleep apnea, and may be repeated to determine the effec-
tiveness of sleep apnea treatment. One study found that the 
use of modafinil used adjunctively with CPAP improved 
subjective daytime sleepiness in PD patients suffering from 
sleep apnea compared to treatment with CPAP alone.60
Conclusion
Sleep disorders occur commonly in PD patients, and 
significantly impair quality of life. Health care providers 
need to be cognizant of the frequency of sleep disorders in 
PD patients, and screen for these disorders during routine 
patient visits. The contribution of medications to sleep 
dysfunction in PD needs to be addressed at these visits, and 
patients may need further formal sleep evaluations if no 
etiology for sleep disruption is found. Further research is 
needed to evaluate the treatment of sleep disorders in PD.Neuropsychiatric Disease and Treatment 2009:5 539
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